News
LXEO
2.900
-0.34%
-0.010
Analysts Conflicted on These Healthcare Names: Lexeo Therapeutics, Inc. (LXEO), Merck & Company (MRK) and OptimizeRx (OPRX)
TipRanks · 1d ago
Lexeo Therapeutics Price Target Maintained With a $23.00/Share by Cantor Fitzgerald
Dow Jones · 1d ago
Lexeo Therapeutics, Inc. (LXEO) Receives a Buy from Oppenheimer
TipRanks · 1d ago
Weekly Report: what happened at LXEO last week (1102-1106)?
Weekly Report · 4d ago
Weekly Report: what happened at LXEO last week (1026-1030)?
Weekly Report · 11/02 10:09
Weekly Report: what happened at LXEO last week (1019-1023)?
Weekly Report · 10/26 10:09
Cantor Fitzgerald Remains a Buy on Lexeo Therapeutics, Inc. (LXEO)
TipRanks · 10/25 10:36
Weekly Report: what happened at LXEO last week (1012-1016)?
Weekly Report · 10/19 10:09
Weekly Report: what happened at LXEO last week (1005-1009)?
Weekly Report · 10/12 10:14
Weekly Report: what happened at LXEO last week (0928-1002)?
Weekly Report · 10/05 10:13
Lexeo Therapeutics Reports Unregistered Equity Issuances Post-Merger
TipRanks · 09/29 20:50
Weekly Report: what happened at LXEO last week (0921-0925)?
Weekly Report · 09/28 10:09
Leerink Partners Keeps Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)
TipRanks · 09/23 13:55
Lexeo Therapeutics Price Target Maintained With a $15.00/Share by Leerink Partners
Dow Jones · 09/23 13:42
Lexeo Therapeutics Is Maintained at Outperform by Leerink Partners
Dow Jones · 09/23 13:42
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX)
TipRanks · 09/23 13:10
Press Release: Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX(TM) for Program Designed to Treat Friedreich Ataxia
Dow Jones · 09/23 12:00
Lexeo Expands Friedreich Ataxia Pipeline Through Mantle Deal, New Collaborations
NASDAQ · 09/22 14:07
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Benzinga · 09/22 12:01
Lexeo Therapeutics enter into agreement to acquire Mantle Therapeutics
TipRanks · 09/22 11:35
More
Webull provides a variety of real-time LXEO stock news. You can receive the latest news about Lexeo Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About LXEO
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).